Rehmann Capital Advisory Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Rehmann Capital Advisory Group’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-92	Closed	-$3.04K	–	2077
2019 Q2	$3.04K	Hold	92	–	–	﹤0.01%	1679
2019 Q1	$3.22K	Hold	92	–	–	﹤0.01%	1637
2018 Q4	$3.06K	Sell	92 -67	-42%	-$2.88K	﹤0.01%	1361
2018 Q3	$8.01K	Buy	159 +24	+18%	+$1.19K	﹤0.01%	1433
2018 Q2	$8.08K	Sell	135 -35	-21%	-$1.81K	﹤0.01%	1416
2018 Q1	$8K	Buy	+170	New	+$7.09K	﹤0.01%	1389

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Rehmann Capital Advisory Group's SUPN Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 92 shares — an estimated $3.04K sold.

Rehmann Capital Advisory Group first reported a position in SUPN in Q1 2018 and held it in 6 quarters. The position peaked at $8.08K in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Rehmann Capital Advisory Group reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Rehmann Capital Advisory Group sold 92 Supernus Pharmaceuticals shares in Q3 2019, an estimated $3.04K.
Rehmann Capital Advisory Group first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Rehmann Capital Advisory Group's Supernus Pharmaceuticals position peaked at $8.08K in Q2 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.